Do high MICs predict the outcome in invasive fusariosis?
Author(s) -
Márcio Nucci,
Jeffrey D. Jenks,
George R. Thompson,
Martin Hoenigl,
Marielle Camargo dos Santos,
Fabio Forghieri,
Juan Carlos Rico,
Valentina Bonuomo,
Leire López-Soria,
Cornelia LassFlörl,
Anna Candoni,
Carolina GarcíaVidal,
Chiara Cattaneo,
Jochem B. Buil,
Ricardo Rabagliati,
María Pía Roiz Mesones,
Carlota Gudiol,
Nicola Fracchiolla,
María Isolina Campos-Herrero,
Mario Delia,
Francesca Farina,
Jesús Fortün,
Gianpaolo Nadali,
Enric Sastre,
Arnaldo Lopes Colombo,
Elena PérezNadales,
Ana AlastrueyIzquierdo,
Livio Pagano
Publication year - 2020
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa516
Subject(s) - posaconazole , fusariosis , voriconazole , itraconazole , medicine , amphotericin b , mortality rate , neutropenia , gastroenterology , caspofungin , mucormycosis , surgery , biology , antifungal , chemotherapy , fusarium , dermatology , horticulture
Background Invasive fusariosis (IF) affects mostly severely immunocompromised hosts and is associated with poor outcome. Since Fusarium species exhibit high MICs for most antifungal agents, this could explain the poor prognosis. However, a clear-cut correlation between MIC and outcome has not been established. Objective To evaluate the correlation between MIC and outcome (6 week death rate) in patients with IF. Methods We performed a multicentre retrospective study of patients with IF who received treatment and had MIC levels determined by EUCAST or CLSI for the drug(s) used during treatment. We compared the MIC50 and MIC distribution among survivors and patients who died within 6 weeks from the diagnosis of IF. Results Among 88 patients with IF, 74 had haematological diseases. Primary treatment was monotherapy in 52 patients (voriconazole in 27) and combination therapy in 36 patients (liposomal amphotericin B + voriconazole in 23). The MIC50 and range for the five most frequent agents tested were: voriconazole 8 mg/L (range 0.5–64), amphotericin B 2 mg/L (range 0.25–64), posaconazole 16 mg/L (range 0.5–64), itraconazole 32 mg/L (range 4–64), and isavuconazole 32 mg/L (range 8–64). There was no difference in MIC50 and MIC distribution among survivors and patients who died. By contrast, persistent neutropenia and receipt of corticosteroids were strong predictors of 6 week mortality. Conclusions Our study did not show any correlation between MIC and mortality at 6 weeks in patients with IF.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom